Fauna Bio: Gleaning Therapeutic Insights From Animals

In Vivo speaks with Ashley Zender, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals. The company's $494m partnership with Eli Lilly is a testament to the value of their approach.